4
IRUS Total
Downloads

Early evaluation of tumour metabolic response using [F-18]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

Title: Early evaluation of tumour metabolic response using [F-18]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas
Authors: Brock, CS
Young, H
O'Reilly, SM
Matthews, J
Osman, S
Evans, H
Newlands, ES
Price, PM
Item Type: Journal Article
Abstract: Quantitation of metabolic changes in tumours may provide an objective measure of clinical and subclinical response to anticancer therapy. This pilot study assesses the value of quantitation of metabolic rate of glucose (MRGlu) measured in mmol min–1ml–1to assess early subclinical response to therapy in a relatively non-responsive tumour. Nine patients receiving the CRC Phase II study schedule of temozolomide were assessed with [18F]fluorodeoxyglucose ([18F]FDG) dynamic positron emission tomography (PET) scans prior to and 14 days after treatment with temozolomide given as 750–1000 mg m–2over 5 days every 28 days. Tumour MRGlu was calculated and compared with objective response at 8 weeks. Pretreatment MRGlu was higher in responders than non-responders. The responding patient group had a greater than 25% reduction in MRGlu in regions of high focal tumour uptake (HFU). Whole tumour changes in MRGlu did not correlate with response. Percentage change in HFU standardized uptake value (SUV) did discriminate the responding from the non-responding patients, but not as well as with MRGlu. Large differences also occurred in the normal brain SUV following treatment. Thus, MRGlu appeared to be a more sensitive discriminator of response than the simplified static SUV analysis. Changes in MRGlu may reflect the degree of cell kill following chemotherapy and so may provide an objective, quantitative subclinical measure of response to therapy.
Issue Date: 1-Feb-2000
Date of Acceptance: 8-Jul-1999
URI: http://hdl.handle.net/10044/1/87087
DOI: 10.1054/bjoc.1999.0971
ISSN: 0007-0920
Publisher: Springer Nature [academic journals on nature.com]
Start Page: 608
End Page: 615
Journal / Book Title: British Journal of Cancer
Volume: 82
Issue: 3
Copyright Statement: © 2000 Cancer Research Campaign. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
temozolomide
positron emission tomography
glioma
metabolic rate of glucose (MRGlu)
CEREBRAL GLUCOSE-UTILIZATION
DNA FLOW-CYTOMETRY
F-18 FLUORODEOXYGLUCOSE
FDG UPTAKE
PROLIFERATIVE ACTIVITY
BREAST-CANCER
BRAIN-TUMORS
PET
FLUORINE-18-FLUORODEOXYGLUCOSE
PARAMETER
Adult
Antineoplastic Agents, Alkylating
Brain Neoplasms
Dacarbazine
Evaluation Studies as Topic
Female
Fluorodeoxyglucose F18
Glioma
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Pilot Projects
Radiopharmaceuticals
Temozolomide
Tomography, Emission-Computed
Humans
Glioma
Brain Neoplasms
Neoplasm Recurrence, Local
Dacarbazine
Fluorodeoxyglucose F18
Antineoplastic Agents, Alkylating
Radiopharmaceuticals
Tomography, Emission-Computed
Pilot Projects
Adult
Middle Aged
Female
Male
Evaluation Studies as Topic
Temozolomide
Science & Technology
Life Sciences & Biomedicine
Oncology
temozolomide
positron emission tomography
glioma
metabolic rate of glucose (MRGlu)
CEREBRAL GLUCOSE-UTILIZATION
DNA FLOW-CYTOMETRY
F-18 FLUORODEOXYGLUCOSE
FDG UPTAKE
PROLIFERATIVE ACTIVITY
BREAST-CANCER
BRAIN-TUMORS
PET
FLUORINE-18-FLUORODEOXYGLUCOSE
PARAMETER
Oncology & Carcinogenesis
1112 Oncology and Carcinogenesis
1117 Public Health and Health Services
Publication Status: Published
Online Publication Date: 2000-01-07
Appears in Collections:Department of Surgery and Cancer



This item is licensed under a Creative Commons License Creative Commons